Peripheral Arterial Disease Trial, Recruiting NCT06003855 Sponsor: VA Office of Research and Development Condition: Peripheral Arterial Disease
Back to Peripheral Arterial Disease

Peripheral Arterial Disease Trial, Recruiting

NCT06003855
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to give written, informed consent
  • People who have a confirmed diagnosis of blocked or narrowed arteries in the lower limbs, based on blood pressure measurements taken at the ankle and arm, and/or medical imaging of the arteries
  • People who have a history of chronic claudication (ongoing leg pain or cramping during walking caused by reduced blood flow)
  • People whose blood pressure, cholesterol, and diabetes medications and treatments have been stable and unchanged for at least 6 weeks before joining

Who may not be able to join:

  • People who experience pain in their legs while resting, or who have wounds or tissue damage caused by poor blood flow to the legs (known as Fontaine stage III and IV peripheral artery disease)
  • People who have recently had a sudden loss of blood flow to a lower limb caused by a blood clot or acute injury
  • People whose ability to walk is limited by conditions other than claudication, such as joint or muscle problems, nerve conditions, heart disease, or lung disease

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Iraklis I Pipinos, MD, Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE

Phone: (402) 995-3542

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 October 2023
Est. completion
30 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Distance walked; Energy expenditure; Reactive oxygen species; Protein expression of ROS-related enzymes; Markers of systemic inflammation; Initial and absolute walking distances; Comprehensive mitochondrial respiratory complex function; Mitochondrial dynamics; Mitochondrial reactive oxygen species production

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov